查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870953

植物药市场按产品类型、剂型、治疗领域、通路和最终用户划分－2025年至2032年全球预测

Botanical Drug Market by Product Type, Formulation, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，植物来源药物市场将成长至 69.8 亿美元，复合年增长率为 7.17%。

关键市场统计数据
基准年 2024 40.1亿美元
预计年份：2025年 43亿美元
预测年份 2032 69.8亿美元
复合年增长率 (%) 7.17%

本文对影响植物药研发的监管压力、供应链韧性和策略专业化进行了简明扼要的基础性概述。

植物药领域融合了传统药用植物科学、现代临床开发和不断发展的法规结构。为了满足未被满足的医疗需求并达到监管核准所需的证据标准，研发人员正日益致力于开发标准化的植物活性成分和特性明确的草药萃取物。这种发展趋势正推动该领域从依赖经验法则的治疗方法转向严格的产品特性分析、品管和以临床为导向的开发路径。

植物药业格局的变革性转变及未来策略重点

植物药领域正经历多项变革，这些变革正在重新定义研发重点和商业模式。分析化学和体学技术的进步使研发人员能够解析复杂的植物基质，识别生物活性成分，并建立以往难以实现的稳定性和功效指标。因此，产品开发过程更加重视标准化的植物活性成分和可重复的萃取方法，以提高监管审批的核准和临床疗效的可预测性。

2025年美国关税对植物药材原料、供应链及策略采购决策的累积影响

2025年美国关税政策的实施为植物药供应链带来了显着的摩擦，尤其是在植物原料、专用萃取设备和某些中间体方面。进口成本的增加迫使研发人员和原料供应商重新评估其采购基础和库存策略。为此，许多企业正在加快供应商多元化计划，并优先考虑近岸外包机会，以降低关税波动风险并最大限度地减少前置作业时间风险。

关键细分洞察揭示了按产品类型、製剂形式、治疗领域、分销管道和最终用户分類的商机视窗。

依产品类型细分，可以发现研发和商业化方法上的差异。草药萃取物正在经历严格的标准化，而复方草药製剂则利用了协同作用的传统优势，但需要先进的分析技术。同时，单味草药萃取物可以进行更精确的化学表征，并拥有更清晰的监管路径。草药补充剂凭藉其自身的标籤和安全要求，在非处方药市场保持着一定的份额，而标准化的草药活性成分则为获得处方级疗效和开展临床开发铺平了道路。

关键区域洞察，包括法规环境、研发能力和市场进入途径，这些因素将影响重点区域的植物药策略

在美洲，监管机构强调对具有疗效宣称的植物产品进行严格的临床证据审查和生产控制。同时，完善的药物监测系统和支付方趋势创造了一个环境，​​在这种环境下，临床差异化和卫生经济学证据对产品的采纳有显着影响。北美生态系统也提供先进的合约研究和生产能力，使申办者能够在拥有稳健的供应链和明确的监管沟通策略的情况下，加速后期专案的进展。

深入了解植物药领域主要企业的策略行动、伙伴关係模式与竞争优势

活跃于植物药领域的主要企业在分析开发、品质系统和临床营运等方面展现出不同的能力建构模式。一些企业优先考虑垂直整合（透过合约种植或专有采购安排确保原材料供应），而其他企业则专注于模组化伙伴关係，将内部药物研发与外包委託製造和临床试验相结合。这些不同的策略模式反映了对投入要素的控制与快速扩展资源弹性之间的权衡。

为产业领导者提供切实可行的建议，以加强植物性疗法开发平臺、降低贸易风险并提高市场准备度

企业应优先考虑分析标准化，并投资于正交表征技术，以确定活性成分并降低批间差异。透过儘早建立严格的化学指纹图谱和稳定性分析，申办者可以简化与监管机构的沟通，并加速从探索性研究到验证性临床试验的过渡。同时，将生物标记策略和患者报告结局纳入研究设计，可以增强证据体系，并有助于证明药物在不同患者群体中具有临床意义的疗效。

调查方法：详细介绍资料来源、分析架构和检验方法，以期对植物来源领域提供可靠的见解。

本研究综合运用多种检验来源，旨在全面了解植物药产业。主要研究相关人员包括对研发主管、法规事务专业人员、供应链经理和商业负责人进行结构化访谈，以收集经验见解并检验新兴趋势。次要资料收集则涵盖监管指南、同行评审的临床文献、生产标准和上市公司披露信息，以验证事实论点并分析战略转变的背景。

结论：摘要植物疗法领域对开发商、监管机构和商业相关人员的策略意义和实践意义

植物药领域正处于关键的转折点，科学严谨性、供应链管理和切实可行的商业化策略共同决定专案的可行性。分析表征和适应性临床设计的进步降低了监管核准的技术门槛，但同时也提高了对证据生成和品管系统的要求。因此，成功的计画必须在科学清晰度和营运稳健性之间取得平衡，以满足监管机构和临床相关人员的需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 加大研发力度，致力于开发植物药製剂的标准化萃取方法
  • 扩大基因组为基础的植物化学型选择在标靶治疗的应用
  • 全球植物药核准途径监管协调工作加速推进
  • 将人工智慧预测模型整合到植物化合物的功效和安全性评估中
  • 利用连续流加工技术扩大客製化草药萃取物的生产规模
  • 开发慢性病综合治疗的多植物协同製剂

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的植物药市场

  • 草药萃取物
    • 复方草药製剂
    • 单味草本萃取物
  • 草药补充剂
  • 标准化草药活性成分

9. 按剂型分類的植物药市场

  • 胶囊
  • 液体萃取物
    • 糖浆
    • 酊剂
  • 粉末
  • 外用药物
    • 奶油
    • 凝胶
    • 软膏

第十章 按治疗区域分類的植物药市场

  • 循环系统
  • 消化器官系统
  • 内分泌系统
  • 呼吸系统
  • 体重管理

第十一章 按分销管道分類的植物药市场

  • 医院药房
  • 网路药房
    • 消费者
    • 第三方平台
  • 零售药房

第十二章 依最终用户分類的植物药市场

  • 诊所
    • 一般诊所
    • 专科诊所
  • 居家医疗
  • 医院

第十三章 各地区的植物药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按类别分類的植物药市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国植物药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Givaudan SA
    • Dr. Willmar Schwabe GmbH & Co. KG
    • Indena SpA
    • Martin Bauer Group GmbH & Co. KG
    • Euromed SA
    • Horphag Research Ltd
    • Sabinsa Corporation
    • PhytoTech Labs Inc.
    • Bioforce AG
    • PhytoLab GmbH & Co. KG
Product Code: MRR-1A1A064C04EA

The Botanical Drug Market is projected to grow by USD 6.98 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.01 billion
Estimated Year [2025] USD 4.30 billion
Forecast Year [2032] USD 6.98 billion
CAGR (%) 7.17%

A concise foundational overview that frames regulatory pressures, supply chain resilience, and strategic professionalization shaping botanical drug development

The botanical drug arena occupies an intersection of traditional pharmacognosy, modern clinical development, and evolving regulatory frameworks. Developers increasingly pursue standardized botanical actives and well-characterized herbal extracts to address unmet therapeutic needs while aiming to meet the evidentiary thresholds required for regulatory approval. This evolution has shifted the sector away from anecdotal remedies toward rigorous product characterization, quality control, and clinically oriented development pathways.

Regulatory clarity is a critical driver of industry behavior. Agencies in major markets are refining guidances for botanical drug dossiers, emphasizing reproducible manufacturing, robust safety profiling, and clearly defined active constituents. Consequently, stakeholders invest in advanced analytical platforms, validated manufacturing processes, and targeted clinical programs that can bridge traditional knowledge with contemporary safety and efficacy standards. Investors and strategic partners now evaluate botanical projects against criteria common to conventional drug development, including proof of mechanism, reproducibility of raw material supply, and scalable production.

Operationally, supply chain resilience has risen to the top of strategic agendas. Cultivation best practices, traceability systems, and supplier qualification programs reduce raw material variability while enabling compliance with good manufacturing practices. At the same time, the commercial environment rewards developers who combine clinical diligence with compelling differentiation, such as novel formulation technologies, targeted therapeutic positioning, and strong intellectual property strategies. Taken together, these dynamics set the stage for a period of professionalization and strategic consolidation within the botanical drug sector.

Transformative Shifts Reshaping the Botanical Drug Landscape and Future Strategic Priorities

The botanical drug sector is undergoing several transformative shifts that are redefining R&D priorities and commercial models. Advances in analytical chemistry and omics technologies now allow developers to deconvolute complex botanical matrices, identify bioactive fractions, and establish stability and potency metrics that were previously difficult to achieve. As a result, product development pathways emphasize standardized herbal actives and reproducible extract profiles to increase regulatory acceptance and clinical predictability.

Concurrently, clinical development paradigms are adapting. Sponsors increasingly design hybrid trials that incorporate biomarkers, adaptive elements, and pragmatic endpoints to demonstrate clinically meaningful effects more efficiently. This methodological adaptation reflects a broader willingness to combine traditional evidence bases with contemporary trial designs, enabling a more nuanced appraisal of safety and efficacy in heterogeneous patient populations.

From a commercial perspective, strategic partnerships between ingredient suppliers, contract development and manufacturing organizations, and clinical research providers are tightening. These alliances enable vertically integrated approaches that streamline raw material sourcing, process scale-up, and regulatory submission readiness. Meanwhile, innovation in formulation science has unlocked new delivery formats-such as optimized liquid extracts and targeted topical vehicles-that improve bioavailability and patient adherence. Together, these shifts create a dynamic environment in which scientific rigor, operational excellence, and creative commercialization converge to redefine what success looks like in botanical drug development.

Cumulative Impact of United States Tariffs 2025 on Botanical Drug Inputs, Supply Chains, and Strategic Sourcing Decisions

The tariff environment introduced in the United States in 2025 has introduced measurable friction into botanical drug supply chains, particularly for raw botanical materials, specialized extraction equipment, and certain intermediate inputs. Increased import costs have incentivized developers and ingredient suppliers to reassess their sourcing footprints and inventory strategies. In response, many organizations have accelerated supplier diversification programs and prioritized nearshoring opportunities that reduce exposure to tariff volatility and minimize lead time risk.

These trade policy shifts also have implications for manufacturing economics and clinical trial timelines. Higher landed costs for imported intermediates pressure margin profiles and can require re-negotiation of supply agreements or incremental investment in domestic processing capabilities. Consequently, sponsors are evaluating the cost-benefit of relocating certain upstream activities closer to final manufacturing sites, while also strengthening contractual protections and hedging strategies to manage price uncertainty.

On a strategic level, tariffs have highlighted the importance of vertical integration and resilient procurement strategies. Organizations that can demonstrate validated domestic supply chains and in-country processing are better positioned to maintain continuity for pivotal programs and commercial launches. Moreover, regulatory dossiers that document consistent raw material provenance and validated manufacturing controls gain added competitive advantage in environments where trade policies can disrupt long-standing sourcing relationships. Ultimately, the 2025 tariff landscape underlines the necessity of proactive procurement planning and adaptive manufacturing strategies to sustain momentum in botanical drug development.

Key Segmentation Insights That Reveal Opportunity Windows Across Product Types, Formulations, Therapeutic Areas, Distribution Channels, and End Users

Insight into product type segmentation highlights divergent R&D and commercialization approaches. Herbal extracts are increasingly pursued with rigorous standardization; multi herb formulations continue to leverage synergistic traditions but require heightened analytical justification, while single herb extracts enable tighter chemical characterization and clearer regulatory pathways. Herbal supplements remain prominent in over-the-counter spaces with distinct labeling and safety obligations, and standardized herbal actives represent the bridge toward prescription-level therapeutic claims and clinical development.

Formulation choices materially influence clinical performance and patient acceptance. Capsules and tablets offer dose consistency and manufacturing scalability, liquid extracts provide flexible dosing and rapid onset characteristics with liquid formats further differentiated by syrups and tinctures that address pediatric and adult dosing requirements, powders enable nutritional or compounding versatility, and topicals deliver localized therapy with subcategories such as creams, gels, and ointments that meet specific dermal absorption and patient preference attributes.

Therapeutic area segmentation guides clinical strategy and target selection. Cardiovascular, digestive, endocrine, respiratory, and weight management indications each present unique endpoints, safety considerations, and patient demographics that shape trial design and regulatory engagement. Distribution channel segmentation drives go-to-market mechanics; hospital pharmacy pathways demand formulary evidence and clinical support, online pharmacy models-operated either direct to consumer or via third party platforms-require robust digital marketing and fulfillment capabilities, and retail pharmacy strategies necessitate point-of-sale visibility and pharmacist education programs.

End user segmentation underscores deployment environments and service models. Clinics, inclusive of general and specialty clinics, prioritize standardized dosing and evidence-backed protocols, home care emphasizes ease of administration and adherence-enhancing delivery systems, and hospitals require integration into institutional formularies, sterile manufacturing where applicable, and cross-disciplinary clinical evidence to support therapeutic adoption. These segmentation insights together inform product positioning, clinical investment focus, and channel strategies for botanical drug developers.

Key Regional Insights Showing How Regional Regulatory Environments, R&D Capabilities, and Market Access Pathways Shape Botanical Drug Strategies Across Major Geographies

In the Americas, regulatory authorities emphasize rigorous clinical evidence and manufacturing controls for botanical products that seek therapeutic claims, while established pharmacovigilance systems and payer dynamics create a landscape where clinical differentiation and health economic evidence can materially influence adoption. North American ecosystems also host advanced contract research and manufacturing capabilities, enabling sponsors to accelerate late-stage programs when supply chains are resilient and regulatory engagement strategies are well-defined.

In Europe, Middle East & Africa, regulatory frameworks vary significantly by jurisdiction, requiring regionally tailored dossier strategies and localized quality documentation. Several European regulators accept well-controlled clinical programs that integrate traditional use with contemporary clinical endpoints, while reimbursement environments differ widely and often depend on health technology assessment outcomes. Across the broader region, strategic partnerships with regional manufacturing and clinical research organizations can unlock access to diverse patient populations and cost-effective trial execution.

In Asia-Pacific, robust herbal medicine traditions coexist with rapidly evolving regulatory standards that increasingly harmonize with global best practices. Many markets in the region possess mature botanical supply chains and strong agricultural capacity, which supports scalable raw material sourcing. Additionally, the region's growing investment in biopharmaceutical R&D and contract services presents opportunities for strategic clinical collaborations and cost-efficient manufacturing scale-up, provided sponsors align development plans with local regulatory expectations and quality standards.

Key Companies Insights Highlighting Strategic Behavior, Partnership Models, and Competitive Differentiators in the Botanical Drug Sector

Leading organizations operating in the botanical space demonstrate a pattern of capability building across analytical development, quality systems, and clinical operations. Some companies prioritize vertical integration-securing raw material supply through contracted cultivation or proprietary sourcing agreements-while others focus on modular partnerships that combine in-house discovery with outsourced manufacturing and clinical execution. These different strategic archetypes reflect a trade-off between control over inputs and flexibility to scale resources quickly.

Partnership models frequently pair botanical expertise with clinical research organizations and specialist CMOs to accelerate translational activities from extract standardization to pivotal trials. Firms that invest early in robust quality assurance systems and comprehensive characterization of active constituents create defensible positions when engaging with regulators and payers. Competitive differentiators include proprietary extraction technologies that enhance bioavailability, formulation platforms that enable novel delivery modes, and curated supply chain traceability that mitigates raw material variability.

Company behaviors also reveal a pragmatic balance between niche specialization and portfolio diversification. Some developers concentrate on narrow therapeutic niches where botanical mechanisms align closely with clinical endpoints, enabling clearer differentiation. Others maintain broader portfolios to capture multiple commercial pathways, combining over-the-counter product lines with clinically developed botanical therapeutics. Across the sector, strong intellectual property strategies, quality certifications, and transparent clinical evidence packages remain decisive factors in partner selection and commercial traction.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Mitigate Trade Risks, and Enhance Market Readiness for Botanical Therapeutics

Companies should prioritize analytical standardization and invest in orthogonal characterization techniques to define active fractions and reduce batch variability. By establishing rigorous chemical fingerprints and stability profiles early, sponsors can streamline regulatory dialogue and accelerate transition from exploratory studies to confirmatory clinical programs. Simultaneously, integrating biomarker strategies and patient-reported outcomes into trial design will strengthen evidentiary packages and help demonstrate clinically meaningful benefit across heterogeneous populations.

To mitigate trade-related risks and tariff exposure, leaders should diversify supplier networks, qualify secondary domestic or regional processors, and consider strategic inventory buffers for critical inputs. Nearshoring key transformation steps and adopting multi-sourcing contracts with explicit quality and delivery clauses will reduce disruption risk and improve control over lead times. In parallel, organizations should pursue manufacturing partnerships that can scale while maintaining validated controls to support both clinical supply and commercial launch readiness.

Commercially, companies must align distribution and engagement models with end user expectations. For hospital and clinic adoption, prioritize clinical education, formulary evidence, and institutional partnerships; for online and retail channels, invest in digital engagement, compliant labeling, and pharmacist or clinician outreach that clarifies therapeutic positioning. Finally, cultivate cross-functional teams that integrate regulatory, clinical, quality, and commercial expertise to ensure development decisions anticipate market access requirements and deliver clear value propositions to payers and providers.

Research Methodology Detailing Data Sources, Analytical Frameworks, and Validation Practices Employed to Deliver Robust Botanical Sector Insights

This research synthesized multiple validated inputs to build a comprehensive understanding of the botanical drug landscape. Primary engagement with industry stakeholders included structured interviews with R&D leaders, regulatory affairs professionals, supply chain managers, and commercial strategists to capture experiential insights and validate emergent trends. Secondary data collection encompassed regulatory guidances, peer-reviewed clinical literature, manufacturing standards, and public company disclosures to triangulate factual assertions and contextualize strategic shifts.

Analytical frameworks combined qualitative thematic analysis with supply chain mapping and regulatory pathway comparison to identify leverage points and risk concentrations. The methodology prioritized traceability of raw material provenance, reproducibility of analytical methods, and alignment between clinical endpoints and regulatory expectations. Cross-validation steps included expert panel reviews and iterative reconciliation of primary and secondary inputs to minimize bias and ensure findings reflect operational realities.

Where applicable, the research applied scenario-based stress testing to examine the operational effects of trade policy shifts, supply disruptions, and formulation transitions. Findings were then synthesized into actionable recommendations that map to distinct corporate functions, enabling practical uptake by product development, quality, and commercial teams.

Conclusion Summarizing Strategic Takeaways and the Practical Implications for Developers, Regulators, and Commercial Stakeholders in Botanical Therapeutics

The botanical drug sector stands at a pivotal juncture where scientific rigor, supply chain discipline, and pragmatic commercialization strategies collectively determine program viability. Advances in analytical characterization and adaptive clinical designs have lowered technical barriers to regulatory acceptance, yet they also raise the bar for evidence generation and quality systems. Therefore, successful programs will couple scientific clarity with operational robustness to satisfy both regulators and clinical stakeholders.

Trade policy dynamics have underscored the importance of resilient sourcing and flexible manufacturing strategies, making procurement and supplier qualification central to program risk management. At the same time, segmentation and regional nuances demand tailored approaches to formulation, distribution, and clinical engagement. Firms that align therapeutic positioning with end user needs and regional regulatory expectations will be better equipped to translate clinical outcomes into clinical uptake.

In sum, the industry's trajectory favors organizations that integrate enhanced analytical capabilities, disciplined supply chain practices, and commercially attuned development plans. These combined strengths will enable botanical drug developers to navigate regulatory challenges, manage external shocks, and capture value through differentiated, evidence-backed therapeutic offerings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing R&D focus on standardized extraction methods for botanical drug formulations
  • 5.2. Rising adoption of genomics-driven selection of plant chemotypes for targeted therapies
  • 5.3. Surge in regulatory harmonization efforts for global botanical drug approval pathways
  • 5.4. Integration of AI predictive modeling in botanical compound efficacy and safety assessment
  • 5.5. Expansion of customized herbal extract manufacturing using continuous flow processing technologies
  • 5.6. Development of multi botanical synergistic formulations for comprehensive chronic disease management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Botanical Drug Market, by Product Type

  • 8.1. Herbal Extracts
    • 8.1.1. Multi Herb Formulation
    • 8.1.2. Single Herb Extract
  • 8.2. Herbal Supplements
  • 8.3. Standardized Herbal Actives

9. Botanical Drug Market, by Formulation

  • 9.1. Capsules Tablets
  • 9.2. Liquid Extracts
    • 9.2.1. Syrups
    • 9.2.2. Tinctures
  • 9.3. Powders
  • 9.4. Topical
    • 9.4.1. Creams
    • 9.4.2. Gels
    • 9.4.3. Ointments

10. Botanical Drug Market, by Therapeutic Area

  • 10.1. Cardiovascular
  • 10.2. Digestive
  • 10.3. Endocrine
  • 10.4. Respiratory
  • 10.5. Weight Management

11. Botanical Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
    • 11.2.1. Direct To Consumer
    • 11.2.2. Third Party Platforms
  • 11.3. Retail Pharmacy

12. Botanical Drug Market, by End User

  • 12.1. Clinics
    • 12.1.1. General Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Botanical Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Botanical Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Botanical Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Givaudan SA
    • 16.3.2. Dr. Willmar Schwabe GmbH & Co. KG
    • 16.3.3. Indena S.p.A.
    • 16.3.4. Martin Bauer Group GmbH & Co. KG
    • 16.3.5. Euromed S.A.
    • 16.3.6. Horphag Research Ltd
    • 16.3.7. Sabinsa Corporation
    • 16.3.8. PhytoTech Labs Inc.
    • 16.3.9. Bioforce AG
    • 16.3.10. PhytoLab GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BOTANICAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BOTANICAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOTANICAL DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 343. AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 344. AFRICA BOTANICAL DRUG MARKET S